After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Cullinan Therapeutics Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Cullinan Therapeutics Inc is $714.45M. A total of 0.16 million shares were traded on the day, compared to an average of 501.43K shares.
In the most recent transaction, Michaelson Jennifer sold 4,693 shares of CGEM for 11.41 per share on Dec 18 ’24. After the transaction, the Chief Scientific Officer now owns 99,760 company shares. In a previous transaction on Dec 18 ’24, Jones Jeffrey Alan sold 4,632 shares at 11.41 per share. CGEM shares that Chief Medical Officer owns now total 114,059.
Among the insiders who sold shares, SUMER JACQUELYN L disposed of 3,482 shares on Dec 18 ’24 at a per-share price of $11.41. This resulted in the Chief Legal Officer holding 90,651 shares of CGEM after the transaction. In another insider transaction, Michaelson Jennifer sold 3,489 shares at $12.52 per share on Dec 12 ’24. Company shares held by the Chief Scientific Officer now total 104,453.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, CGEM has a high of $30.19 and a low of $9.24.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. CGEM’s latest balance sheet shows that the firm has $290.47M in Cash & Short Term Investments as of fiscal 2021. There were $0.00 in debt and $11.75M in liabilities at the time. Its Book Value Per Share was $10.80, while its Total Shareholder’s Equity was $425.37M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CGEM is Buy with a score of 5.00.
